Wall Street analysts forecast that Align Technology, Inc. (NASDAQ:ALGN) will announce sales of $358.40 million for the current quarter, according to Zacks. Seven analysts have provided estimates for Align Technology’s earnings, with estimates ranging from $357.45 million to $359.13 million. Align Technology posted sales of $278.59 million in the same quarter last year, which would indicate a positive year over year growth rate of 28.6%. The firm is scheduled to issue its next quarterly earnings results on Monday, November 6th.

On average, analysts expect that Align Technology will report full-year sales of $358.40 million for the current fiscal year, with estimates ranging from $1.38 billion to $1.43 billion. For the next financial year, analysts expect that the firm will post sales of $1.69 billion per share, with estimates ranging from $1.66 billion to $1.79 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Align Technology.

Align Technology (NASDAQ:ALGN) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $0.85 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.12. Align Technology had a return on equity of 23.87% and a net margin of 19.18%. The firm had revenue of $356.50 million for the quarter, compared to analysts’ expectations of $343.43 million. During the same quarter in the previous year, the company earned $0.62 earnings per share. The firm’s quarterly revenue was up 32.3% compared to the same quarter last year.

Several analysts have recently commented on the stock. Robert W. Baird reissued a “buy” rating on shares of Align Technology in a research note on Tuesday. Goldman Sachs Group, Inc. (The) increased their price target on shares of Align Technology to $210.00 and gave the company a “buy” rating in a research note on Friday. Piper Jaffray Companies reissued a “buy” rating and set a $200.00 price target on shares of Align Technology in a research note on Monday, September 11th. Leerink Swann reissued an “outperform” rating and set a $199.00 price target (up from $194.00) on shares of Align Technology in a research note on Friday, July 28th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $205.00 price target (up from $200.00) on shares of Align Technology in a research note on Monday, August 7th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $179.82.

Align Technology (ALGN) opened at 184.50 on Friday. The company has a market cap of $14.79 billion, a PE ratio of 63.18 and a beta of 1.55. The firm has a 50 day moving average price of $175.22 and a 200 day moving average price of $143.46. Align Technology has a 12-month low of $83.27 and a 12-month high of $186.10.

COPYRIGHT VIOLATION NOTICE: “Align Technology, Inc. (ALGN) Expected to Post Quarterly Sales of $358.40 Million” was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/16/align-technology-inc-algn-expected-to-post-quarterly-sales-of-358-40-million.html.

Hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC boosted its stake in Align Technology by 36.7% in the first quarter. AQR Capital Management LLC now owns 94,715 shares of the medical equipment provider’s stock valued at $10,865,000 after acquiring an additional 25,422 shares during the last quarter. Stifel Financial Corp boosted its stake in Align Technology by 11.6% in the first quarter. Stifel Financial Corp now owns 75,393 shares of the medical equipment provider’s stock valued at $8,643,000 after acquiring an additional 7,834 shares during the last quarter. Karp Capital Management Corp bought a new position in Align Technology in the first quarter valued at approximately $2,620,000. American Century Companies Inc. boosted its stake in Align Technology by 2,236.0% in the second quarter. American Century Companies Inc. now owns 221,009 shares of the medical equipment provider’s stock valued at $33,178,000 after acquiring an additional 211,548 shares during the last quarter. Finally, Oppenheimer & Co. Inc. bought a new position in Align Technology in the second quarter valued at approximately $1,768,000. 81.72% of the stock is currently owned by hedge funds and other institutional investors.

Align Technology Company Profile

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Get a free copy of the Zacks research report on Align Technology (ALGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.